Werewolf Therapeutics, Inc.
HOWL
$1.28
$0.043.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -85.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -85.86% |
| Cost of Revenue | -35.82% | 2.49% | 82.64% | 15.59% | -84.18% |
| Gross Profit | -160.86% | -9.23% | -134.58% | -153.55% | 75.17% |
| SG&A Expenses | -7.64% | -3.60% | 3.68% | 6.64% | 22.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.74% | 0.49% | 40.69% | 13.04% | 42.09% |
| Operating Income | 7.48% | -4.83% | -56.98% | -85.10% | -212.51% |
| Income Before Tax | -4.25% | -11.71% | -69.96% | -101.24% | -238.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.25% | -11.71% | -69.96% | -101.24% | -238.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.25% | -11.71% | -69.96% | -101.24% | -238.35% |
| EBIT | 7.48% | -4.83% | -56.98% | -85.10% | -212.51% |
| EBITDA | 7.40% | -5.19% | -59.22% | -89.30% | -228.53% |
| EPS Basic | -0.88% | -3.67% | -39.76% | -64.16% | -176.36% |
| Normalized Basic EPS | -4.21% | -3.70% | -39.79% | -64.19% | -167.63% |
| EPS Diluted | 5.97% | -3.67% | -39.76% | -64.16% | -196.65% |
| Normalized Diluted EPS | -5.49% | -3.70% | -39.79% | -64.19% | -164.40% |
| Average Basic Shares Outstanding | 3.36% | 7.74% | 21.62% | 22.58% | 22.40% |
| Average Diluted Shares Outstanding | 2.13% | 7.74% | 21.62% | 22.58% | 23.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |